Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISNU-1: FOLFOXIRI + Bevacizumab vs FOLFOX + Bevacizumab in mCRC with High CTCs
NCT01640405Phase 3Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jul 2012
- Primary completion
- Nov 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Started Jul 2012; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01640405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640405.